The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The pharmaceutical formulation useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compounds, or hydrolysis-resistant mononucleoside triphosphate salts. The present invention also provides P
1
-(2′-deoxycytidine 5′-)P
4
-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P
1
-(2′-deoxycytidine 5′-)P
4
-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.
本发明提供了一种治疗
水肿性视网膜疾病的方法。该方法包括施用包含抗
水解 P2Y 受体激动剂的药物制剂,以刺激从视网膜下和视网膜间隙清除病理性外来液体,从而减少与视网膜脱离和视网膜
水肿相关的上述液体的积聚。P2Y 受体激动剂可与常用于治疗
水肿性视网膜疾病的治疗剂和辅助剂一起使用。本发明中有用的药物制剂包括具有增强的抗细胞外
水解能力的 P2Y 受体激动剂,如二核苷多
磷酸化合物或抗
水解的单核苷
三磷酸盐。本发明还提供了 P
1
-(2′-脱氧
胞苷 5′-)P
4
-(
尿苷 5′-)
四磷酸,四(碱
金属)盐,如四
钠、四
锂、四
钾和混合(四碱
金属)盐。本发明进一步提供了一种药物制剂,其中包含 P
1
-(2′-脱氧
胞苷 5′-)P
4
-(
尿苷-5′-)
四磷酸四碱
金属盐,以及药学上可接受的载体。